UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $905.00 million. The enterprise value is $911.71 million.
Important Dates
The last earnings date was Monday, March 2, 2026, before market open.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 48.68 million shares outstanding. The number of shares has increased by 12.22% in one year.
| Current Share Class | 48.68M |
| Shares Outstanding | 48.68M |
| Shares Change (YoY) | +12.22% |
| Shares Change (QoQ) | +2.44% |
| Owned by Insiders (%) | 2.07% |
| Owned by Institutions (%) | 78.23% |
| Float | 38.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.22 |
| Forward PS | 3.78 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.01
| Current Ratio | 4.01 |
| Quick Ratio | 3.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -32.10% |
| Return on Invested Capital (ROIC) | -110.91% |
| Return on Capital Employed (ROCE) | -81.06% |
| Weighted Average Cost of Capital (WACC) | 11.46% |
| Revenue Per Employee | $377,278 |
| Profits Per Employee | -$527,471 |
| Employee Count | 291 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 0.97 |
Taxes
In the past 12 months, UroGen Pharma has paid $78,000 in taxes.
| Income Tax | 78,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +61.23% in the last 52 weeks. The beta is 1.37, so UroGen Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | +61.23% |
| 50-Day Moving Average | 20.31 |
| 200-Day Moving Average | 19.13 |
| Relative Strength Index (RSI) | 40.97 |
| Average Volume (20 Days) | 916,118 |
Short Selling Information
The latest short interest is 8.02 million, so 16.47% of the outstanding shares have been sold short.
| Short Interest | 8.02M |
| Short Previous Month | 9.34M |
| Short % of Shares Out | 16.47% |
| Short % of Float | 20.74% |
| Short Ratio (days to cover) | 11.79 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $109.79 million and -$153.49 million in losses. Loss per share was -$3.19.
| Revenue | 109.79M |
| Gross Profit | 97.34M |
| Operating Income | -124.86M |
| Pretax Income | -153.42M |
| Net Income | -153.49M |
| EBITDA | -124.56M |
| EBIT | -124.86M |
| Loss Per Share | -$3.19 |
Full Income StatementBalance Sheet
The company has $120.46 million in cash and $130.09 million in debt, with a net cash position of -$9.63 million or -$0.20 per share.
| Cash & Cash Equivalents | 120.46M |
| Total Debt | 130.09M |
| Net Cash | -9.63M |
| Net Cash Per Share | -$0.20 |
| Equity (Book Value) | -105.47M |
| Book Value Per Share | -2.18 |
| Working Capital | 139.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$162.44 million and capital expenditures -$289,000, giving a free cash flow of -$162.73 million.
| Operating Cash Flow | -162.44M |
| Capital Expenditures | -289,000 |
| Free Cash Flow | -162.73M |
| FCF Per Share | -$3.34 |
Full Cash Flow StatementMargins
Gross margin is 88.66%, with operating and profit margins of -113.73% and -139.81%.
| Gross Margin | 88.66% |
| Operating Margin | -113.73% |
| Pretax Margin | -139.74% |
| Profit Margin | -139.81% |
| EBITDA Margin | -113.45% |
| EBIT Margin | -113.73% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.22% |
| Shareholder Yield | -12.22% |
| Earnings Yield | -17.02% |
| FCF Yield | -18.04% |
Analyst Forecast
The average price target for UroGen Pharma is $29.29, which is 57.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $29.29 |
| Price Target Difference | 57.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 53.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -6.02 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.02 |
| Piotroski F-Score | 1 |
